Skip to contentGOLDSTEIN DOV A MD — CEMPRA, INC. insider: 119 transactions · InsiderLensGOLDSTEIN DOV A MD
- Chief Financial Officer at VICURON PHARMACEUTICALS INC · on record since Sep 5, 2003
- Director at CEMPRA, INC. · on record since Mar 23, 2012
- Director at R&R ACQUISITION VI, INC · on record since Feb 15, 2012
- Chief Financial Officer at BioAge Labs, Inc. · on record since Apr 24, 2026
- Director at Durata Therapeutics, Inc. · on record since Jul 25, 2012
- 10% owner at Durata Therapeutics, Inc. · on record since Jul 25, 2012
- Director at Esperion Therapeutics, Inc. · on record since Jun 25, 2013
- Director at Loxo Oncology, Inc. · on record since Jul 31, 2014
- CFO and Treasurer at Loxo Oncology, Inc. · on record since Jul 31, 2014
- 10% owner at Loxo Oncology, Inc. · on record since Jul 31, 2014
- 10% owner at R&R ACQUISITION VI, INC · on record since Feb 16, 2017
- Director at Ohr Pharmaceutical Inc · on record since Jul 16, 2019
- Director at Gain Therapeutics, Inc. · on record since Mar 17, 2021
- Director at Coya Therapeutics, Inc. · on record since Dec 28, 2022
Insider trading activity of GOLDSTEIN DOV A MD
- Transactions on record
- 119
- since Sep 5, 2003
- Open-market buys
- 8
- $26.1M
- Open-market sells
- 16
- $63.3M
- Companies traded
- 10
- last filing Apr 24, 2026
Figures computed from official regulatory filings — methodology.
Companies where GOLDSTEIN DOV A MD has traded
- BioAge Labs, Inc.16 tx · $820.4K · Apr 24, 2026
- Coya Therapeutics, Inc.8 tx · $19.1K · Jan 6, 2026
- Gain Therapeutics, Inc.4 tx · Jun 25, 2025
- Ohr Pharmaceutical Inc7 tx · $158K · Sep 12, 2022
- R&R ACQUISITION VI, INC10 tx · May 1, 2020
- Esperion Therapeutics, Inc.26 tx · $60.5M · Jun 8, 2018
- CEMPRA, INC.26 tx · $13.2M · Mar 9, 2017
- Loxo Oncology, Inc.12 tx · $5.6M · Apr 3, 2015
- Durata Therapeutics, Inc.3 tx · $10M · Jul 25, 2012
Track record of GOLDSTEIN DOV A MD
Statistical track record
Free- Open-market buys
- 9
- Last buy
- Jan 3, 2023
Win rates and median returns are available with a free account (5 insiders/month).
Create a free account→Transaction history of GOLDSTEIN DOV A MD
Co-insiders of GOLDSTEIN DOV A MD
This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →
7 tx · Sep 10, 2004
AISLING CAPITAL III LPDurata Therapeutics, Inc. +1
| Company | Filed | Type | Qty | Price | Value · USD | Src |
|---|
| Apr 24, 2026 | ExerciseD | -3,542 | 0.00 USD | $0 | SEC |
| Apr 24, 2026 | Exercise | 3,542 | 4.38 USD | $15.5K | SEC |
| Mar 3, 2026 | ExerciseD | -3,542 | 0.00 USD | $0 | SEC |
| Mar 3, 2026 | Exercise | 3,542 | 4.38 USD | $15.5K | SEC |
| Feb 19, 2026 | AwardD | 110,000 | 0.00 USD | $0 | SEC |
| Feb 3, 2026 | ExerciseD | -3,541 | 0.00 USD | $0 | SEC |
| Feb 3, 2026 | Exercise | 3,541 | 4.38 USD | $15.5K | SEC |
| Jan 21, 2026 | ExerciseD | -3,542 | 0.00 USD | $0 | SEC |
| Jan 21, 2026 | Exercise | 3,542 | 4.38 USD | $15.5K | SEC |
| Jan 15, 2026 | Sell | -8,974 | 18.43 USD | $165.4K | SEC |
| Jan 15, 2026 | Sell | -1,923 | 21.08 USD | $40.5K | SEC |
| Jan 15, 2026 | ExerciseD | -27,000 | 0.00 USD | $0 | SEC |
| Jan 15, 2026 | Exercise | 27,000 | 8.39 USD | $226.5K | SEC |
| Jan 15, 2026 | Sell | -4,440 | 19.45 USD | $86.4K | SEC |
| Jan 15, 2026 | Sell | -11,663 | 20.54 USD | $239.6K | SEC |
| Jan 6, 2026 | AwardD | 10,000 | 0.00 USD | $0 | SEC |
| Aug 19, 2025 | ExerciseD | -17,557 | 0.00 USD | $0 | SEC |
| Aug 19, 2025 | Exercise | 17,557 | 1.09 USD | $19.1K | SEC |
| Jun 25, 2025 | AwardD | 15,000 | 0.00 USD | $0 | SEC |
| Feb 25, 2025 | AwardD | 5,000 | 0.00 USD | $0 | SEC |
| Feb 20, 2025 | AwardD | 170,000 | 0.00 USD | $0 | SEC |
| Jan 3, 2025 | AwardD | 5,000 | 0.00 USD | $0 | SEC |
| Jun 26, 2024 | AwardD | 15,000 | 0.00 USD | $0 | SEC |
| Jan 19, 2024 | AwardD | 5,000 | 0.00 USD | $0 | SEC |
| Jun 26, 2023 | AwardD | 10,500 | 0.00 USD | $0 | SEC |